The efficacy of topical sodium pentaborate formulation on hemorrhoid disease: A randomized, double-blind, placebo-controlled trial

被引:1
|
作者
Sahin, Fikrettin [1 ]
Farshbaf-Khalili, Azizeh [2 ]
Alihosseini, Samin [3 ]
Sarbakhsh, Parvin [4 ]
Pirouzpanah, Mohammad Sadegh [5 ]
Aysan, Erhan [6 ]
Dogan, Aysegul [1 ]
Gharekhani, Afshin [7 ]
Khoshbaten, Manouchehr [8 ]
Pirouzpanah, Mohammad-Bagher [9 ]
机构
[1] Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, Istanbul, Turkiye
[2] Tabriz Univ Med Sci, Aging Res Inst, Phys Med & Rehabil Res Ctr, Tabriz, Iran
[3] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[4] Tabriz Univ Med Sci, Sch Publ Hlth, Dept Stat & Epidemiol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Fac Med, Res & Dev Off, Satin Tan Kimia Co,Pharmaceut Incubator, Tabriz, Iran
[6] Yeditepe Univ, Fac Med, Dept Gen Surg, Istanbul, Turkiye
[7] Tabriz Univ Med Sci, Dept Clin Pharm Pharmacotherapy, Drug Appl Res Ctr, Sina Hosp, Tabriz, Iran
[8] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran
[9] Tabriz Univ Med Sci, Stem Cell & Regenerat Med Inst, Tabriz, Iran
关键词
Sodium pentaborate pentahydrate; Hemorrhoid disease; Randomized controlled trial; BORIC-ACID; IN-VITRO; BORON; PATHOPHYSIOLOGY; EXPRESSION; WOUNDS;
D O I
10.1016/j.heliyon.2024.e27215
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The topical application of boron has been significantly associated with intensifying wound healing. Using 3% boric acid in deep wounds significantly contributes to wound healing and reduces the duration of hospitalization in the intensive care. The objective of this study was to assess the therapeutic impact of a topical gel containing sodium pentaborate pentahydrate on the management of wounds resulting from grade 1 to 3 hemorrhoids. Methods: In this randomized double-blind placebo-controlled trial, we applied a topical gel consisting of sodium pentaborate pentahydrate 3% on 206 eligible patients with the diagnosis of grade 1, 2, and 3 hemorrhoid diseases. Then patients were randomly allocated to two groups of sodium pentaborate pentahydrate or placebo gel with a ratio of 1:1 and received the allocated gel for four weeks. Patient hemorrhoid symptoms severity, hemorrhoid degree, and anoscopy findings were compared before and after the trial. Results: Before the intervention, symptom severity (p > 0.05) and anoscopy findings (p = 0.815) were similar between the two groups. Subsequent to the intervention, a majority of patients in the intervention group experienced a reduction in anal itching compared to the placebo group [adjusted mean difference (aMD) 95% CI: -1.98 (-2.2 to -1.8), p = 0.007]. Moreover, resting pain [aMD (95% CI): -1.37 (-1.6 to -1.1), p = 0.015], pain during defecation [aMD (95% CI): -2.19 (-2.4 to -2.0), p = 0.005], feeling a lump in the anus (aMD (95% CI): -0.71 (-1.2 to -0.2), p = 0.011), bleeding during defecation (41.7% vs. 66.9%, p = 0.027), and hemorrhoid degree (p < 0.001) in the intervention group was less than the placebo group. Conclusion: Our findings indicate the effectiveness of the study gel on hemorrhoid symptoms and anoscopy findings in patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Probiotic Supplementation in Chronic Kidney Disease: A Double-blind, Randomized, Placebo-controlled Trial
    Borges, Natalia A.
    Carmo, Flavia L.
    Stockler-Pinto, Milena B.
    de Brito, Jessyca S.
    Dolenga, Carla J.
    Ferreira, Dennis C.
    Nakao, Lia S.
    Rosado, Alexandre
    Fouque, Denis
    Mafra, Denise
    JOURNAL OF RENAL NUTRITION, 2018, 28 (01) : 28 - 36
  • [42] Estrogen for Alzheimer's disease in women - Randomized, double-blind, placebo-controlled trial
    Henderson, VW
    Paganini-Hill, A
    Miller, BL
    Elble, RJ
    Reyes, PF
    Shoupe, D
    McCleary, CA
    Klein, RA
    Hake, AM
    Farlow, MR
    NEUROLOGY, 2000, 54 (02) : 295 - 301
  • [43] Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease
    Martinuzzi, Andrea
    Liava, Alexandra
    Trevisi, Enrico
    Frare, Mara
    Tonon, Caterina
    Malucelli, Emil
    Manners, David
    Kemp, Graham J.
    Testa, Claudia
    Barbiroli, Bruno
    Lodi, Raffaele
    MUSCLE & NERVE, 2008, 37 (03) : 350 - 357
  • [44] Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
    Sandborn, WJ
    Hanauer, SB
    Katz, S
    Safdi, M
    Wolf, DG
    Baerg, RD
    Tremaine, WJ
    Johnson, T
    Diehl, NN
    Zinsmeister, AR
    GASTROENTEROLOGY, 2001, 121 (05) : 1088 - 1094
  • [45] Effects of ETyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
    DiFrancisco-Donoghue, Joanne
    Rabin, Ely
    Lamberg, Eric M.
    Werner, William G.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2014, 1 (04): : 348 - 353
  • [46] Ethyl-EPA in Huntington disease - A double-blind, randomized, placebo-controlled trial
    Puri, BK
    Leavitt, BR
    Hayden, MR
    Ross, CA
    Rosenblatt, A
    Greenamyre, JT
    Hersch, S
    Vaddadi, KS
    Sword, A
    Horrobin, DF
    Manku, M
    Murck, H
    NEUROLOGY, 2005, 65 (02) : 286 - 292
  • [47] A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson's disease
    Chong, K. K.
    Lim, S. Y.
    Manap, M. A. A. A.
    Lim, J. L.
    Low, S. C.
    Mahadeva, S. K.
    Tan, A. H.
    MOVEMENT DISORDERS, 2018, 33 : S194 - S194
  • [48] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
  • [49] Meniett Device in Meniere Disease: Randomized, Double-Blind, Placebo-Controlled Multicenter Trial
    Russo, Francesca Yoshie
    Yann Nguyen
    De Seta, Daniele
    Bouccara, Didier
    Sterkers, Olivier
    Ferrary, Evelyne
    Bernardeschi, Daniele
    LARYNGOSCOPE, 2017, 127 (02): : 470 - 475
  • [50] A randomized, double-blind, placebo-controlled trial of hydrogen water in Parkinson's disease
    Yoritaka, A.
    Takanashi, M.
    Hirayama, M.
    Ohta, S.
    Hattori, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 311 - 311